Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ginkgo Bioworks Holdings Q2 2024 GAAP EPS $(0.11) Misses $(0.07) Estimate, Sales $56.21M Beat $43.14M Estimate

Author: Benzinga Newsdesk | August 08, 2024 05:04pm
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.07) by 57.14 percent. The company reported quarterly sales of $56.21 million which beat the analyst consensus estimate of $43.14 million by 30.30 percent. This is a 30.24 percent decrease over sales of $80.57 million the same period last year.

Posted In: DNA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist